As reported by The Pharma Times, the global pharma company GlaxoSmithKline (GSK), has signed a deal with the Moscow-based JSC Binnopharm manufacture and sell a number of GSK’s cervical cancer, rotavirus and pneumococcal vaccines in its domestic market.
Under this agreement, GSK will be supplying all the ingredients, technology and expertise in order to make the vaccines while Binnopharm, a unit of oil-to-telecoms group Sistema, will put them together, and package and sell them in Russia.
The agreement covers the following vaccines:
- Cervarix – this protects againts HPV infections which cause cervical, head and neck cancers
- Rotarix – this protects against rotavirus which causes gastroenteritis and diarrhoea
- Synflorix – this protects against strains of Streptococcus pneumoniae that can cause illnesses such as pneumonia and meningitis.
Speaking of the agreement, the two firms stated, ‘The local manufacture of these vaccines should help Russia to modernise its National Immunisation Calendar in the future, adding additional vaccination against highly prevalent infections,’
‘This agreement is an example of the flexible approach we are taking to make innovative vaccines more available in emerging markets through local partnerships,’ said GSK’s head of emerging markets and Asia Pacific, Abbas Hussain.
Are you looking for a position in the UK pharmaceutical industry? Click here to search our current pharmaceutical jobs online now.